Trial Profile

A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFN alpha-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha kinoid (Primary) ; Montanide ISA-51
Indications Glomerulonephritis; Lupus nephritis; Systemic lupus erythematosus
Focus Adverse reactions; First in man
Sponsors Neovacs

Most Recent Events

28 Jun 2016 Results of extended follow-up data published in the Rheumatology
09 Sep 2015 According to Neovacs media release, company has presented extended follow-up data at the 11th International Congress on Systemic Lupus Erythematosus (SLE).
17 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com